An accurate assessment strategy of PD-L1 expression is needed, including re-biopsy, as we described in the evaluation of HER2 status.30 We believe that reconsidering the PD-L1 expression as a predictor for PD-1 inhibitor efficacy in GC could be helpful. This evidence concerns the gene ERBB2 and gastric cancer.